Please login to the form below

Not currently logged in
Email:
Password:

Amarillo Biosciences appoints Stephen Chen chair and CEO

He replaces Joseph Cummins, who will remain as the US biotech's chief operating officer

Amarillo Biosciences has selected Dr Stephen Chen, one of its directors, to take on the roles of CEO and chair.

Dr Chen takes over from Joseph Cummins, who will remain as the US biotech's president and chief operating officer.

Chen has been at Texas-based Amarillo since 1996, and has over 30 years' experience in the pharma and healthcare industry.

During this time he has held executive positions in R&D and business at several major pharma companies, including Burroughs Wellcome (now GlaxoSmithKline), Miles Pharmaceuticals (now Bayer), ICI America (now AstraZeneca), and Ciba-Geigy (now Novartis).

Since May 1992, he has been CEO of STC International, a US-based healthcare investment firm.

As CEO at Amarillo, Chen will lead operations at the company, which focus on research into the use of low-dose, oral interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough and HIV-related infections.

27th February 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics